CEO Update: Monday 25th September

Last week we held our latest Women In Biotech event in central London. We were lucky enough to have two thought-provoking talks from our guest speakers Professor Melissa Hanna Brown from Pfizer, and Dr Emma Sceats from CN Bio, who gave us their insights into the role of women as both intrapreneurs and entrepreneurs in the life sciences. A big thank you to Bristows LLP for hosting.

BIA responds to the Treasury’s Patient Capital Review

The BIA has today (Friday 22 September) welcomed the government’s proposal to establish a new National Investment Fund to support the growth of innovative UK bioscience companies.

Touchlight Genetics Press Release: World leading DNA technology is expanding its operations in London as it grows to meet global DNA demand.

Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial scale DNA in a two-week process – a technology that is disrupting the decades old fermentation approach. The process uses two enzymes, and basic benchtop laboratory equipment to produce DNA of any sequence for therapeutic applications.

BIA responds to Prime Minister Theresa May’s Florence speech

BIA CEO, Steve Bates,responds to Prime Minister Theresa May’s Florence speech.

BIA Webinar - Funding and solving R&D challenges with NC3Rs, AstraZeneca and Actual Analytics

This week the BIA held a member webinar entitled ‘Funding and solving R&D challenges: scientific, commercial and animal welfare drivers behind NC3Rs and CRACK IT Challenges’, which presented a fascinating case study of innovative collaboration from the CRACK IT project.

BIA and MHRA publish report following joint conference ‘Innovation in life sciences in a changing and dynamic environment’

The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the sector to discuss some hot topics and important developments that are having an impact on the changing and dynamic UK life sciences ecosystem.

PureTech Health Notes US Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech

PureTech Health plc, an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers programme. The patent broadly covers methods of assessing a mental or physical condition of a subject, using phonetic structures, or phones, extracted from speech audio waveforms. The issued patent is exclusively licensed under an agreement with the Massachusetts Institute of Technology (MIT) and provides coverage through at least 2032.

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD

Zug, Switzerland – September 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and its partner in Japan, Shionogi & Co., Ltd, announced that a Phase 3 study evaluating INTUNIV® (guanfacine hydrochloride prolonged release) in adult patients with attention deficit hyperactivity disorder (ADHD) in Japan has positive topline results, and the study met the primary endpoint. This is the first clinical trial evaluating INTUNIV in adult patients (18 years old and over) with ADHD.

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

Cambridge and Newcastle, UK, 20th September, 2017: Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development Company, and IONTAS Limited (IONTAS), a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today announced a collaboration for the development of ADCs for difficult-to-treat cancers. As part of the agreement, IONTAS will generate novel, fully human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink® and its in-house portfolio of novel toxins.

Synpromics announces gene therapy research partnership with Solid Biosciences

Edinburgh, UK, 20th September 2017 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).